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Abstract 
In the late 20s, after Sir Alexander Fleming discovered the penicillin, a large interest in 
the search for compounds with antimicrobial activity produced by microorganisms emerged. 
This event marked the beginning of a new era of antibiotic discovery, where numerous scientist 
would screen for antibiotics in microorganisms, mostly from the soil. 
Previous work undertaken at LMB-BioFIG, suggest that ΔphoQ mutation in 
Stenotrophomonas maltophilia D457 strain is associated to an increased antimicrobial activity. 
The main focus of this work was to: determine the existence of compounds with antimicrobial 
activity produced by the aforementioned mutant; determine its spectrum of activity and 
optimize the culture conditions that are optimal to its production. To answer these questions, 
a series of biologic susceptibility assays were performed, with both the parental D457 strain 
and D457ΔphoQ strain. Namely the cross-streak assay, agar-well diffusion assay and drop-
diffusion assay. For the later, different culture conditions for the producing strains were tested 
in order to better understand which conditions favour the compound production, and also, 
sequential extractions with different organic solvents with different polar characteristics were 
made to fractionate the obtained batches regarding the polarity of its content, and tested for 
biologic activity.  
Finally, in an attempt to unveil the compound of interest, protein quantification, thin layer 
chromatography and gas chromatography-mass spectrometry analysis were performed on all 
extracts to better elucidate the nature and structure of the compound. 
This work revealed that the compound of interest is of non-polar nature produced in low 
concentrations, around 0.1 g/L. Was only present in the ethyl acetate fraction, with inhibitory 
activity against the test strains. In neither biologic assay did the parental strain show any 
inhibitory activity. Additionally, it was revealed by protein quantification assays that the mutant 
strain secreted almost 3-fold more protein than the parental strain. The results obtained by 
GC-MS suggest that the compound of interest resembles with the 2,3-dihydroxybenzoic acid, 
with possible presence of cyclic structures, such as aromatic rings in its molecular structure. 
However, further analytical procedures must be undertaken to clarify and confirm the structure 
of the secreted compounds by D457ΔphoQ strain. 
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Resumo 
No final dos anos 20, após Sir Alexander Fleming ter descoberto a penicilina, emergiu 
um grande interesse na pesquisa de compostos com atividade antimicrobiana a partir de 
microrganismos. Este evento marcou o início de uma nova era na descoberta de antibióticos, 
onde vários cientistas focaram os esforços na pesquisa de antibióticos em microrganismos, 
especialmente com origem no solo em particular espécies do género Penicillium e 
Streptomyces. No entanto, nem todos os microrganismos são suscetíveis a estes compostos. 
Determinadas bactérias e fungos, possuem uma enorme diversidade de mecanismos que 
conferem resistência a esses compostos. Estes mecanismos de defesa podem basear-se em 
reações enzimáticas que levam à alteração da estrutura do composto que levam à sua 
inativação, em aumento de número de bombas de efluxo membranares que rapidamente 
expulsam os compostos do meio intracelular ou finalmente em alterações no local de ligação 
do composto que levam à interrupção da ligação entre o antibiótico e o local de ação. A 
presença dos referidos mecanismos é de elevada relevância medica quando presentes em 
bactérias patogénicas, uma vez que dificulta o tratamento de doenças pelos métodos 
convencionais. Atualmente, o número de mortes associadas a infeções causadas por 
bactérias multirresistentes ronda os 25000 apenas na União Europeia, e este estigma custa 
cerca de 1,5 mil milhões de euros todos os anos. 
Stenotrophomonas maltophilia D457 é uma bactéria gram-negativa, popular por ser um 
organismo com uma exímia capacidade de resistência a antibióticos e metais pesados, ainda, 
na qualidade de agente patogénico oportunista, está vulgarmente associado a infeções em 
pacientes cujo sistema imunitário se encontra debilitado e a infeções originadas em hospitais. 
As infeções mais frequentes causadas por este agente patogénico são associadas a 
septicemias causadas por cateteres e infeções respiratórias em doentes com fibrose cística. 
Trabalho desenvolvido previamente no LMB-BioFIG, sugere que uma mutação de 
frame-knockout mutação do gene phoQ na estirpe Stenotrophomonas maltophilia D457 está 
associada a um aumento na produção de um composto com atividade antimicrobiana. O gene 
phoQ faz parte de um sistema de dois componentes PhoP-PhoQ regulador de virulência em 
diversas bactérias patogénicas. O foco principal deste trabalho foi: determinar a existência de 
compostos com atividade antimicrobiana produzidos pelo mutante mencionado anteriormente; 
determinar qual o seu espectro de atividade e otimizar as condições de cultura que são mais 
favoráveis para a sua produção. Para responder a estas questões, diversos ensaios de 
atividade biológica foram realizados com ambas as estirpes, quer a parental D457 quer a 
mutante D457ΔphoQ. Nomeadamente ensaios de cross-streak, difusão de poços de agar e 
difusão de gotas. Para este último, diferentes condições de crescimento das estirpes 
produtoras foram testados para determinar quais as condições que favoreciam a produção 
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dos compostos com atividade antimicrobiana, ainda, extrações sequenciais usando diferentes 
solventes orgânicos, (diclorometano, acetato de etilo e metanol) foram realizadas com o intuito 
de fracionar os produtos obtidos do crescimento das estirpes produtoras de acordo com a 
polaridade dos seus conteúdos, culminando no teste da sua atividade biológica contra estirpes 
da biblioteca do laboratório cuja característica principal é a sua elevada resistência a 
antibióticos. 
Finalmente, na tentativa de desvendar qual o composto de interesse, ensaios de 
quantificação de proteína, cromatografia em camada fina e cromatografia gasosa-
espectrometria de massa foram realizados a todos os extratos para melhor elucidar a natureza 
e a estrutura do composto. 
Este trabalho revelou que o composto de interesse é de natureza apolar e é produzido 
em baixas concentrações, menos de 0,1 g/L. Encontra-se apenas presente na fração de 
acetato de etilo. Esta fração revelou atividade biológica contra diversas estirpes teste, 
nomeadamente, Acinetobacter haemolyticus VR, Stenotrophomonas maltophilia D457R, 
Pseudomonas aeruginosa PAO1, Escherichia coli ESLB, Bacillus cereus B4379 e 
Enterococcus faecalis ATCC 29212. Em nenhum ensaio de atividade biológica, a estirpe 
parental revelou inibição de crescimento das estirpes teste. Ensaios de quantificação de 
proteína revelaram que o mutante apresenta uma maior produção de proteínas 
comparativamente com a estirpe parental, num grau de grandeza 3 vezes superior à parental. 
Os resultados do GC-MS sugeriram que o composto com atividade biológica se assemelha 
com o ácido 2,3-dihidroxi benzoico e poderá possuir estruturas cíclicas como anéis aromáticos 
na sua estrutura. No entanto, adicionais procedimentos analíticos serão necessários para 
clarificar e confirmar a estrutura dos compostos produzidos pelo mutante ΔphoQ. 
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1. Introduction 
1.1 Microbes and Antibiotics 
Even though chemical warfare is considered, by modern society, the most dangerous 
and politically incorrect way of resolving conflicts, bacteria and fungi don’t share the same 
opinion. In fact, microorganisms are veterans in this subject. Since very long, we’re aware that 
Penicillium rubrum, Penicillium notatum Lactococcus lactis and Streptomyces griseus produce 
very important molecules that are used to compete against other species in the environment 
(Fleming 1929; Rogers 1928; Schatz et al. 1944). In 1942, Dr. Selman Waksman used for the 
first time the term “antibiotic” to refer a substance with the ability to kill bacteria and fungi or 
slow eventually to a stop their growth (Waksman 1947). 
Generally, the production of these molecules grant a fair advantage when microbes are 
put across other species that are competing for the same food/energy resources. Yet, the 
production of these antibiotics doesn’t come without a cost. The microorganism that produces 
a certain antibiotic, has to be, at some point, resistant to that same compound otherwise he 
would die. Both the production and resistance to a certain compound, requires extra energetic 
and material burdens to the microorganism making him less fit in some occasions. For 
example, when two strains, one producing and one sensitive to the antibiotic, are put together, 
obviously the producing strain is going to be the fittest and consequently will have higher 
growth rates than the sensitive, because the toxin/antibiotic produced will eliminate or at least 
slow the competitors’ growth. On the other hand, if a producing strain and a resistant-only 
strain are put together, the tables will turn and the producing strain won’t be as fit anymore, 
because the resistant-only bacteria doesn’t have the extra energetic and material cost from 
producing the antibiotic and as it is resistant to the antibiotic it won’t have any effect on its 
growth. The remaining scenario is when a sensitive strain and a resistant-only strain are put 
across, the one who will reproduce more will be the one with less energetic/material costs, 
which in this case, is the sensitive. This is the basic concept of the “rock-paper-scissors” 
evolutionary game (Lenski & Riley 2002). So it appears that there is some kind of “love-hate” 
relation between microbes and antibiotics. 
Currently, the ability to produce antibiotics present in some microorganisms is being 
exploited by the pharmaceutical industry. Probably the most popular case of society exploring 
these incredible features dates back the late 1920’s when Dr. Alexander Fleming discovered 
that when he cultured Penicillium rubrum in an appropriate substrate the fungi would exude a 
substance with anti-microbial properties, later named Penicillin (Fleming 1929). This event 
triggered a large interest in researching of novel antibiotics produced by microbes marking the 
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beginning of modern era of antibiotic discovery (Beutler 2010). This discovery was a major 
step forward in drug discovery and healthcare, as it made possible to cure many former life-
threatening bacterial infections. Additionally, the discovery of penicillin stimulated the interest 
in the screening for antibiotics from other living organisms, as is the case of streptomycin from 
Streptomyces. However we are now at a point that the amount of effort that is being put into 
the discovery of novel antibiotics is not following the increase of antibiotic resistant strains, and 
this growing threat is of high importance to public health (Hirschler 2013). 
1.2 Antibiotic resistance 
The World Health Organization (WHO), has repeatedly stated that we are in a situation 
that requires immediate attention. Multidrug resistant bacteria, commonly called as super-
bugs, currently kill over 25,000 patients yearly in the European Union alone and around 1.5 
billion euros per year are spent trying to prevent more causalities (Norrby et al. 2009). Coupled 
with the lack of interest of drug companies to research for new antibiotics, the bad use of 
current antibiotics in health care is drastically increasing the rate that these super-bugs are 
being selected. Difficult access to quality-assured medicines and uninformed society often 
leads to patients to take incomplete courses of prescribed treatment or in other cases to resort 
to lower-quality medicines, these two instances combined create an optimum set of conditions 
to select and preserve multidrug-resistant strains (Sun, Jackson, Gordon A Carmichael, et al. 
2009; Togoobaatar et al. 2010). 
While in most developed countries the health services can be trained and debriefed in 
order to regulate the prescribing of antimicrobials, the same cannot be as easily applied to 
more remote and sub-developed regions, where the lack of training and supervision of health 
personnel, low to none methods of rapid diagnostic facilities to support treatment decisions 
and, most disturbing of all, where economic incentives are given to those who prescribe and 
deliver medicines as well as inappropriate marketing of pharmaceuticals that stimulates 
improper medicine prescribing, often contributes to the bad use of antibiotics (Sun, Jackson, 
Gordon A. Carmichael, et al. 2009). This negligence towards antimicrobial use lead us to the 
state that we are today were the old generation of antibiotics are becoming less effective and 
the new ones are beginning to fail too early. In the year 2000 Linezolid - a promising antibiotic 
from the oxazolidinone class used to treat serious infections caused by Gram-positive bacteria 
resistant to several other antibiotics - was approved by the Food and Drug Administration 
(FDA) and a year later the first resistant strain emerged in a oncologic ward of an hospital in 
the United States (Schmidt 2004; Bozdogan & Appelbaum 2004). 
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Hospitals are the perfect stage for the drug-resistant pathogens to arise, mostly 
because there are two main mechanisms for a sensitive strain to become resistant to a given 
antibiotic. For a sensitive strain to become resistant, one of two things have to occur: either a 
spontaneous mutation in its genome or horizontal gene transfer (HGT) from contact with a 
second naturally or previously acquired resistant strain (Palmer & Kishony 2013). Basal 
mutation rates are drastically increased when sub-lethal concentrations of drugs are given to 
treat an infection, this happens when a patient decides to not complete the full cycle of 
treatment. It was shown that when given sub-lethal concentrations of bactericidal antibiotics, 
such as β-lactams, quinolones and aminoglycosides to E. coli and S. aureus, these bacteria 
would produce reactive oxygen species (ROS) (Kohanski et al. 2007). Certain ROS, including 
hydroxyl radicals, can easily damage de DNA and lead to the accumulation of mutations 
(Kohanski et al. 2010). Error-prone DNA polymerases are activated when breaks are found in 
the DNA as a part of the SOS stress response system. These breaks are induced by sub-lethal 
doses of certain families of antibiotics like quinolones. The repair of these breaks increases 
the chance of mutation which might lead to antibiotic resistance (Cirz et al. 2005). Sub-lethal 
doses of antibiotic can also increase the rate of HGT, even low environment concentrations 
resulting from anthropogenic activities like agriculture, livestock or other industrial activities 
(Gillings 2013). The transference of mobile genetic elements, such as transposons, insertion 
sequences, integrons, integrating conjugative elements or pathogenicity islands through 
transformations, conjugation or transduction is strongly induced when sub-lethal 
concentrations of antibiotics in general (Aminov 2011). This facilitates the diffusion of 
previously existing resistance genes to microorganisms that were previously sensitive. 
1.2.1 Mechanisms of action vs. resistance 
Different antibiotics can possess different mechanisms of action. The table 1 below 
show the different families of antibiotics with its chemical class, biological source, spectrum of 
activity and mode of action. 
Facing such diversity in antibiotics and mechanisms of action, bacteria managed to 
come up with an even greater diversity of mechanisms which confer resistance to these 
molecules. There are three major strategies that bacteria possess to become resistant to 
antibiotics. Firstly, some microorganisms are capable of changing the antibiotic’s chemical 
structure. This mechanism is present in bacteria who produce β-lactamases, these enzymes 
cleave the β-lactam ring of the penicillin, or other β-lactams, which leaves the antibiotic 
obsolete (Petrosino et al. 2009). Secondly, some bacteria have an increased the number of 
efflux pumps in their cellular membrane. These efflux pumps can rapidly expel the antibiotic 
that enter the cell, keeping the internal antibiotic concentration to a minimum (Webber 2002). 
Lastly, bacteria also have the ability to modify chemically or genetically the target site of the 
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antibiotic, once the target is modified the antibiotic cannot bind and resistance is acquired 
(Nikaido 2009). 
Some antibiotics are associated with more than one mechanism of resistance. It has 
been described all three mechanisms of resistance in Tetracycline, its noticeable why bacteria 
are highly adaptive microorganisms. Bacteria easily uptake tetracycline, however active efflux 
pumps can just as easily discard any molecule of tetracycline who enters the bacteria (Levy 
1992). Another way tetracycline can become obsolete is by a bacteria producing a protein 
which protects the ribosome blocking the association of the antibiotic with the ribosome, 
allowing it to resume protein synthesis (Taylor & Chau 1996). Finally, it has been also 
described inactivation of the molecule by enzymatic activity. Even though it’s the rarest of all 
three, it has been described in human gut Bacteroides a gene named tet (X) which codifies a 
44-kDa cytoplasmic protein which chemically alters tetracycline in the presence of oxygen and 
NADPH (Speer et al. 1991; Chopra & Roberts 2001). 
Table 1 - Chemical class of antibiotics and their characteristics 
Chemical class Example Source Spectrum Mode of action 
Β-Lactams     
Penicillins Penicillin G P. notatum Gram-positive Bacteria Inhibits steps in cell wall 
synthesis and murein 
assembly. 
Cephalosporins Cephalothin Cephalosporium species 
Semisynthetic β-
Lactams 
    
Aminopenicillins Ampicillin, Amoxicillin  Gram-positive and Gram-
negative 
bacteria 
Inhibits steps in cell wall 
synthesis and murein 
assembly. 
Clavulanic Acid Clavamox (Clav. Acid + 
Amoxicillin) 
Streptomyces 
clavuligerus 
Suicide inhibitor of β-
Lactamases. 
Monobactams Aztreonam Chromobacter 
violaceum 
Inhibits steps in cell wall 
synthesis and murein 
assembly. Carboxypenems Imipenem Streptomyces cattleya 
Peptides     
Polypeptides Polymyxin Bacillus polymyxa Gram-negative bacteria Damages cytoplasmic 
membranes 
 Bacitracin Bacillus subtilis Gram-positive bacteria Inhibits steps in murein 
(peptidoglycan) 
biosynthesis 
and assembly 
Glycopeptides Vancomycin Streptomyces 
orientales 
Gram-positive bacteria, 
Staphylococcus 
aureus 
Lincomycins Clindamycin Streptomyces 
lincolnensis 
Gram-positive and Gram-
negative 
bacteria 
anaerobic Bacteroides 
Inhibits translation 
(protein synthesis) 
Aminoglycosides     
 Streptomycin Streptomyces griseus Gram-positive and Gram-
negative bacteria 
Inhibit translation (protein 
synthesis)  
Gentamicin Micromonospora 
species 
Gram-positive and Gram-
negative 
Peudomonas 
Macrolides Erythromycin Streptomyces erythreus Gram-positive and 
Gram-negative bacteria 
not enteric, Neisseria, 
Legionella, Mycoplasma 
Inhibit translation (protein 
synthesis) 
Polyenes     
 Amphotericin B Streptomyces nodosus Fungi (Histoplasma) Inactivates membranes 
containing sterols  Nystatin Streptomyces noursei 
Rifamycins Rifampicin Streptomyces 
mediterranei 
Gram-positive and Gram-
negative 
Inhibits transcription 
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1.3 Research and development of antibiotic agents 
There are several phases 
during antibiotic research and 
development (R&D) that a new 
drug applicant (NDA) has to be 
submitted to before being 
accepted into the market. A novel 
approach in drug discovery is 
trending where small scientific of 
academic groups focus on the 
early stages of antibiotic development, namely the preclinical stage (Livermore 2011) and once 
promising results regarding a NDA  are found, a bigger, industrial company, previously 
associated with the research group, takes control of the project, mainly because the next 
phases require a bigger monetary investment (Tralau-Stewart et al. 2009; Rosenblatt 2013). 
During the first phase of drug discovery, the most important issue to be addressed is making 
sure that the NDA is active against a broad range of organisms and also that it isn’t toxic when 
administered. Initial susceptibility testing begins with a regular “dip-disk” test or a “drop test”, 
which is applied to a freshly inoculated lawn of a bacterial strain to an agar plate. After the 
plates are incubated at optimal growth conditions halos of inhibition are measured to assess 
the presence of antimicrobial activity (Dougherty & Pucci 2012). Toxicity assays are usually 
bacteria, Mycobacterium 
tuberculosis 
(eubacterial RNA 
polymerase) 
Tetracyclines Tetracycline Streptomyces species Gram-positive and Gram-
negative bacteria, 
Rickettsias 
Inhibit translation (protein 
synthesis) 
Semisynthetic 
Tetracyclines 
Doxycycline  Gram-positive and Gram-
negative bacteria, 
Rickettsias Ehrlichia, 
Borellia 
Inhibit translation (protein 
synthesis) 
Chloramphenicols Chloramphenicol Streptomyces 
venezuelae 
Gram-positive and Gram-
negative bacteria 
Inhibit translation (protein 
synthesis) 
Quinolones Nalidixic acid Synthetic Mainly Gram-negative 
bacteria 
Inhibits DNA  
 replication 
Fluoroquinolones Ciprofloxacin Synthetic Gram-negative and some  
Gram-positive bacteria 
(Bacillus anthracis) 
Inhibits DNA  
 replication 
Growth factor 
analogues 
    
 Sulfanilamide, 
Gantrisin, Trimethoprim 
Synthetic Gram-positive and Gram-
negative bacteria 
Inhibits folic acid 
metabolism (anti-folate) 
 Isoniazid (INH) Synthetic 
Mycobacterium tuberculosis 
Inhibits mycolic acid 
synthesis; analog of 
pyridoxine (Vit B6) 
 para-aminosalicylic 
acid  (PAS) 
Synthetic Anti-folate 
Fig. 1 - The research and development process. 
(Rosenblatt 2013) 
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performed with human cell lines or in more advanced phases of development on animals in 
certified facilities. 
When working with natural products, one important aspect is the complexity of the 
fermented broths. Once antimicrobial activity is observed in a sample, the active molecule must 
be identified and isolated from the complex broth which contains several different molecules. 
Occasionally, the molecule(s) of interest is(are) in much lower concentration than most of the 
remaining constituents, which makes the isolation process particularly difficult (Gray et al. 
2006). To elucidate the chemical structure of the biologically active molecule present in a 
fermentation broth, series of assays have to be conducted. Firstly the compound must be 
isolated via solvent extractions, ion-exchange methods, gel filtration, and chromatography, and 
only after, resorting to nuclear magnetic resonance (NMR) and X-ray crystallography we are 
able to clearly identify the molecular structure (Exarchou et al. 2005; Exarchou et al. 2006; 
Tatsis et al. 2007). All these procedures combined can take several months to complete (Gootz 
1990). 
After all the time and work invested, the isolated molecule isn’t ready to move up to the 
clinical phases. It is still possible to properly change the molecule’s structure in order to 
improve its activity, pharmacokinetics, toxicity and to avoid becoming obsolete by mechanisms 
of resistance (Dougherty & Pucci 2012). During this phase efforts are focused on 
understanding the Structure-Activity Relationship (SAR) to elucidate which modifications result 
in a better and more stable antibiotic. Only after demonstrating the efficiency and stability of 
the lead compound, it will undergo further clinical trials (FDA 2006). The clinical trials are 
divided in 3 phases: during the first trial phase a drug is given to a small group of healthy 
volunteers (20 to 80 volunteers) to determine safety and dosing; in the second the same drug 
is then given to slightly bigger group of sick patients (100 to 500) in order to test for efficacy 
and further safety; during the third phase the universe of the patients who are administered the 
drug is greatly increased (1000 to 5000) for further efficacy and safety testing and to compare 
the results of the tested drug with other standard or experimental drugs (National Institutes of 
Health 2001). After passing these 3 phases the drug is green-lit for commercialization, and 
sometimes a determined period of time is established by the FDA called post-market 
surveillance studies period to keep under watch the effects of the drug in the general population 
(National Institutes of Health 2001). 
However, drug development does not cease once a drug enters clinical trials. The FDA 
pointed out 5 major aspects in their guidelines made available in 2009 that have to be 
addressed in parallel during early clinical trials so that a NDA can be vetted to move through 
all the clinical phases. The first aspects that have to be meticulously questioned are the 
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demonstration of in vitro and in vivo activity against targeted pathogens; secondly, a study of 
which culture conditions interfere with the assessment of antimicrobial activity is required to 
establish quality control parameters; comprehending how the body fluids and secretions 
interact with the in vitro activity of the NDA is of major importance as well a full description of 
the NDA’s mechanism of action or inhibition (MOA/MOI), killing efficiency, potential for 
resistance development and cross resistance to other antimicrobials. This is especially 
relevant when dealing new antibiotics with new MOA (CDER 2009), as the behaviour of the 
drug can be more unpredictable, finally, the possible interactions with other antimicrobial 
agents or any other drugs has to be carefully studied (Dougherty & Pucci 2012). Following 
these guidelines provided by the FDA will, in the long run, increase the success rate of an 
NDA. 
During the final phase of clinical trials, the main focus point is quality control, together 
with in vitro antimicrobial assessment (CDER 2009). Data from the quality control assessments 
of both the clinical trials and the in vitro assays as well as the results of antimicrobial efficiency 
are presented in a final report to the authorities so an antibiotic can be approved or delayed 
for more testing. The time scale, from lead isolation and optimization to commercialization, 
takes in average a total of 14 years in the US (DiMasi et al. 2003) during this time a massive 
amount of money is invested and if, for some reason, the drug fail to meet the requirements to 
enter the market all the invested money is lost. In fact, the attrition rates in the road of antibiotic 
discovery and development are incredibly high. In average, out of 10,000 substances 
compounds screened only around a 250 will show antimicrobial activity and will go through 
pre-clinical trials, but unfortunately only about 5 qualify as candidates during the testing in the 
pre-clinical trials. This means that from discovery to approval each compound can has a 99% 
chance of not being approved (European Comission 2008). The most common issues 
associated with such high attrition rate are poor pharmacokinetics and toxicity (Kassel 2004). 
It’s extremely important being able to identify as early as possible which candidates are more 
likely to be dropped out later in the process. The ability to identify such candidates allows to 
avoid wasting money and resources on a candidate that will not be approved. 
Rules and techniques have been developed to help identify molecules with propensity 
to have drug-like characteristics. In 1997 Christopher A. Lipinski elaborated a set of five rules, 
later called “Lipinski’s Rule of Five”. When the characteristics of a drug candidate obeyed the 
5 rules, Lipinski would consider the candidate to have “drug-likeness” and would be likely that 
it would be orally active in humans. The rules are as follows: the molecular structure of the 
candidate should not have more than 5 hydrogen bond donors and 10 hydrogen bond 
acceptors; its molecular mass should be lower than 500 Dalton and should not have an 
octanol-water partition coefficient (logP) greater than 5 (Lipinski 2004; Lipinski et al. 2001). 
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After proving the relevance of this rule of thumb, other rules were created in the same genera, 
like the “Rule of Three” which is an adaptation for lead compounds. According to this rule, a 
compound which do not comply with more than one of the rules bellow isn’t considered to have 
lead-likeness, and the rules are: octanol-water partition coefficient log P not greater than 3; 
molecular mass less than 300 Daltons; not more than 3 hydrogen bond donors; not more than 
3 hydrogen bond acceptors; not more than 3 rotatable bonds. Statistics shows that candidates 
who obey to this rule of thumb have lower attrition rates during clinical trials (Leeson & 
Springthorpe 2007; Congreve et al. 2003). 
Another approach to reduce attrition rates is by preforming ADME (absorption, 
distribution, metabolism and excretion) assessment in the early stages of drug development. 
Information gathered with these assays, allow to understand the critical reasons why most drug 
candidates are abandoned. That information can be used to either help during the 
development phase, by tailoring the molecule to better suit the requirement needs or to 
abandon the research as early as possible (Kassel 2004; Wang & Urban 2004). There is a 
wide range of information that can be collected from ADME assays. The rate at which a drug 
is dissolved under the various conditions of the human body, which helps understand how 
easily a NDA is entering the organism; this can be assessed with simple assays like the 
“saturation shake-flask” (Saal & Petereit 2012). Membrane permeability to the NDA helps 
understand if the drug is able to diffuse through barriers, such as membranes present in our 
gastro-intestinal tract, in order to enter the transportation systems, these assays are regularly 
performed in vitro using human cell lines or other mammal cell lines (Gleeson 2008). In vitro 
or in silico determination of the ionization constant (pKa, the concentration at which both 
neutral species and ionized from are equally distributed) helps further understanding of its 
solubility and permeability, also, pKa data aids better understanding the binding mechanisms 
of therapeutic events which might lead to optimization of chemical reactions (Wang & Urban 
2004). Lypophilicity (LogP and LogD) data is important to predict solubility, permeability and 
also transport mechanism, once again is the “saturated shake-flask” is used but with a more 
lipophilic solution, however more advanced techniques are available to determine de LogP 
and LogD of a NCE like liposome chromatography, immobilized artificial membrane and 
chromatography approaches (Wohnsland & Faller 2001; Wang & Urban 2004). Chemical 
stability is tested by incubating the NCE in various extreme conditions like pH and temperature, 
followed by a quantification of the molecule as a whole using detection systems like LC-MS or 
HPLC, this is important to assure that the molecule stays unchanged and active as it goes 
through all the different conditions inside the human organism (Kibbey et al. 2001; Wang & 
Urban 2004). The main determinant of drug concentration in the blood is the hepatic 
metabolism stability, because even though a drug is orally absorbed there must not be any 
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degradation by the liver enzymes (Obach 2001; Wang & Urban 2004). The most reliable data 
on this subject is usually gathered from human experiment in clinical trials due to the complex 
and extreme conditions present in our organism. Still, in vitro models are being studied using 
a vast array of liver enzymes, microsomes, isolated hepatocytes, so that lead optimization 
initiate before the clinical trials. 
In the past, many scientists and companies searched for new active molecules in 
natural products, not only antibiotics but also other molecules with possible medicinal use. 
During a long time, 39 % of the drug substances available in the pharmaceutical industry were 
natural products or inspired by a natural compound, and 60-80% of the antibiotics and anti-
cancer drugs were derived from natural products (Cragg et al. 1997). Though it seems that this 
trend is changing. Between 2001 and 2008 was registered a drop of 30% in natural-product-
based development projects (Harvey 2008). This is due to advances in high-throughput 
screening technologies. Such technologies, allowed us to unveil a broader range of synthetic 
molecules in a more cost-effective way with the vastest therapeutic indications, such as, anti-
cancer, anti-infective/antibiotic, anti-diabetic, anaesthetic, analgesics etc. (Ganesan 2008) . 
Still, the pharmaceutical industry, in general, is withdrawing from the use of natural products 
in drug research because of the difficulties that they come across. Even though natural 
products are easily assimilated by the our organism, there are still some downsides, for 
example the complexity of the molecular structure of the products, the slowness of working 
with biological material which sometimes can also interfere with intellectual property rights and, 
in some cases, the availability of the raw materials (Lam 2007; Rishton 2008). These 
mentioned issues combined with the fact that in the past couple of years, several drug 
companies abandoned the research for antibiotics and focused on more profitable lines of drug 
development, such as drugs for chronic diseases like cancer, reduces the chances of 
discovering new and more efficient antibiotics (Hirschler 2013). 
1.4 Stenotrophomonas maltophilia 
Since 1947, when first isolated from pleural fluid, this bacteria have seen its name 
corrected three times. The first name attributed in 1947 was Bacterium bookeri and soon was 
re-named to Pseudomonas maltophilia (Hugh & Leifson 1963). Later, through RNA analysis it 
was concluded that it had more resemblance with the Xanthomonas genus, and so it was 
named X. maltophilia (Swings et al. 1983). It was only in 1995 through DNA and rRNA studies 
plus sequencing and mapping of the 16s rRNA genes that the distinction of S. maltophilia and 
other members of the genus became clear (Nesme et al. 1995). 
This gram-negative bacteria is an opportunistic pathogen, usually associated to 
infections in patients who already have their immune system debilitated. However, It’s 
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importance as nosocomial pathogen is increasing noticeably In the last years (Denton & Kerr 
1998a; Brooke 2012). The most regular infections caused by this pathogen are usually 
associated with catheter-related bacteraemia/septicaemia and respiratory infections in cystic 
fibrosis patients. Other forms disease manifestation are pneumonia, bloodstream bacteraemia, 
soft skin and tissue infections, osteomyelitis, meningitis, endocarditis, urinary tract infection, 
biliary sepsis among others (Brooke 2012). This bacteria can be found not only in hospitals but 
practically anywhere in the world, from shower caps, tap water, natural bodies of water, soil, 
fruits, vegetables, raw meat, fish (Denton & Kerr 1998). Currently, the most alarming fact about 
this bacteria is that genomic analysis revealed that this microorganism have a remarkable 
capacity for drug and heavy metal resistance. Several genetic determinants which confer 
resistance to different classes of antibiotics via alternative mechanisms have been identified 
in its genome (Crossman et al. 2008). 
1.4.1 Stenotrophomonas maltophilia D457 vs. ΔphoQ 
Bacteria do not possess specialized organs to evaluate its surrounding  environment; 
however, it present mechanisms that allow to process the information from its surrounding 
environment, such as, pH, O2 concentration, luminosity, and other external conditions. These 
mechanisms are usually associated with two-component systems (TCS) (Stock et al. 2000). It 
has been discussed that these TCS are possible targets for antimicrobial agents (Barrett & 
Hoch 1998; Stephenson & Hoch 2002; Furuta et al. 2005; Watanabe et al. 2003). 
The phoPQ operon is one of the two-component systems which are related to the 
regulation of virulence in many gram-negative bacteria. This regulation is mediated by the 
stimulation of the histidine sensor kinase PhoQ by extracellular conditions, namely the 
concentration of bivalent ions and changes in pH, and the response regulator PhoP (Véscovi 
et al. 1997; Garcia Véscovi et al. 1994). Described responses to these types of stimuli include 
alteration of lipopolysaccharide biosynthesis and increased resistance to several antibiotics 
(Zwerschke 2012). Also it has been reported that pathogenic bacteria become more virulent in 
the presence of low concentrations of Mg2+ (Soncini et al. 1996). During the phenotypic 
assessment of a novel S. maltophilia D457 mutant by frame knockout of the phoQ gene, 
evident changes on the morphology, growth and motility patterns were revealed. When 
cultured in the same media, the D457ΔphoQ mutant showed morphologic changes and 
increased swimming and swarming mobility compared with the D457 parental of a magnitude 
32 fold and 15 fold for swimming and swarming respectively (Zwerschke 2012). 
However, what was more interesting was the apparent evidence of an antibacterial 
substance that was being produced by the D457ΔphoQ mutant but not produced by the 
parental strain. The main purposes of antibiotic resistance mechanisms is conferring antibiotic 
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tolerance to bacteria which produce antibiotics. Hence, the remarkable natural antibiotic 
resistance that S. maltophilia possess might be related with antibiotic production itself. It has 
been described production of nonribosomal peptides by species from the same genus as S. 
maltophilia (Royer et al. 2004; Birch & Patil 1985). Nonribosomal peptides are molecules with 
a vast array of biologic functions, being antimicrobial activity one of the most relevant in modern 
medicine (Schwarzer et al. 2003). Evidence gathered by previous work undertaken regarding 
the production of a putative compound with microbial activity by S. maltophilia D457ΔphoQ 
mutant, combined with published work which reveals production of potent antimicrobial across 
species in the same genus, and with recent in depth genome studies that suggest that the 
genus Xanthomonas might be a promising reservoir for bioactive nonribosomal peptides 
(Royer et al. 2013). 
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2. Thesis goals 
Previous studies have showed that several species from the same genus of 
Stenotrophomonas maltophilia are capable of producing compounds with high antimicrobial 
activity (Hashidoko et al. 1999; Birch & Patil 1985). Additionally, previous work suggested that 
a frame knock-out mutation in the phoQ gene of S. maltophilia, would generate severe 
phenotypic changes in comparison to the parental strain. In addition to this phenotypic 
changes, there was also the possibility that the mutant would start producing a compound with 
antimicrobial characteristics. (Royer et al. 2013). Taking this into account, we hypothesised 
that a knockout frame mutation in the phoQ gene of S. maltophilia D457, might induce the 
activation of a metabolic pathway which otherwise would be down-regulated or inhibited, and 
the result would be a production of compounds with antimicrobial activity. 
In this work, we aimed to understand the differences between the mutant strain and the 
parental strain, regarding the production of the compound with antimicrobial activity to 
determine if the presence of such compounds were exclusive to the mutant. The best culture 
conditions at which this, or these, compound(s) is(are) produced and its yield, as well as its 
spectrum of activity against drug resistant strains were assessed by culturing both the parental 
strain and the mutant in different conditions and submitting the broths in which they were grown 
to susceptibility tests. Moreover, knowing the chemical characteristics of this/these unknown 
compounds was of our interest since it would help understand what chemical structures would 
confer biological activity to these compounds. This information would be relevant to the R&D 
community in order to develop molecules with the same characteristics. Therefore, GC-MS 
analysis was performed in the attempt to elucidate the chemical characteristics, including 
molecular structure of the unknown compounds. 
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3. Materials and Methods 
3.1 Bacterial strains and growth conditions 
The bacterial strains used in this study are listed in table 2. The strains were divided in 
two categories: producing strains and test strains, the first being the strains which are being 
screened for production of compounds with antimicrobial activity and the later the strains which 
the samples/extracts are tested on. Each bacterial strain was stored in cryovials at -80º Celsius 
in a glycerol solution at a concentration of 20%. Fresh cultures were started by inoculating 5 
millilitre (ml) of lysogeny broth (LB),(10 grams per litre (g/L) of tryptone, 5 g/L of yeast extract 
and 5 g/L NaCl) (Bertani 1951), with 15 microliter (μl) of stock culture stored at -80º C. All 
strains were incubated over night at 37 ºC in an incubator with orbital shaking at 200 rpm. For 
further use, the strains were transferred to appropriate medium and conditions as described 
below. Every manipulation of stocks and cultures was performed in aseptic environments using 
either a Bunsen burner or a Telstar Bio II A laminar flow chamber. 
Table 2- Strains used in this work. 
Bacterial Strains Genotype / Relevant Features Reference / Source 
Producing Strains   
Stenotrophomonas maltophilia 
D457 
multiresistanta pathogenic strain, 
isolated from clinical sources 
(Lira et al. 2012) 
Stenotrophomonas maltophilia 
D457 ΔphoQ 
D457 with an in frame knockout of 
SMD_2062 (phoQ); tetracycline 
resistant, sacB 
(Zwerschke 2012) 
Test Strains   
Escherichia coli MultiR clinical multidrug resistant isolate Laboratory collection 
Escherichia coli ESBL clinical isolate, producer of 
extended spectrum β-lactamase 
Laboratory collection 
 
Pseudomonas aeruginosa PAO1 clinical isolate Laboratory collection 
 
Bacillus cereus ATCC 11778 Reference strain from a clinical 
isolate 
From ATCC collection 
 
Enterococcus faecalis ATCC 
29212 
Reference strain from a clinical 
isolate 
From ATCC collection 
Stenotrophomonas maltophilia 
D457R 
Overexpression of SmeDEF 
multidrug efflux system which 
increases resistance to tet, chl, ery 
and quinolones 
Laboratory collection 
(Alonso & Martinez 
2001) 
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Staphylococcus aureus MRSA Clinical β-lactam resistant isolate Laboratory collection 
(Monteiro et al. 
2012)(Monteiro et al. 
2012)(Monteiro et al. 
2012)(Monteiro et al. 
2012)(Monteiro et al. 
2012)(Monteiro et al. 
2012) 
Acinetobacter haemolyticus VR Clinical isolate, vancomycin 
resistant 
Laboratory collection 
 
3.2 Swimming and Swarming 
Motility assays were conducted in order to assure that the ΔphoQ mutant strain was 
still phenotypically stable. By comparison of swimming and swarming patterns between D457 
and ΔphoQ was possible to monitor the stability of the phenotype. 
The swimming and swarming assays were mainly preformed like previously described 
(Rashid & Kornberg 2000). The swimming motility was carried out by inoculating a single 
colony of an over-night culture grown in lysogeny agar (LA, 1.5% wt/vol) at 37 ºC to the centre 
of a LA plate that contained 0.3% (wt/vol) of commercial agar. The plates were sealed with 
Parafilm® M to prevent dehydration and incubated at 37 ºC for 16 hours. For the swarming 
motility assay, 1 µl of over-night culture grown in LB at 37 ºC 200 rpm was transferred to the 
centre of a LA plate with 0.8% [wt/vol] commercial agar. The plates were sealed and incubated 
at 37 ºC for 16 hours and further 48 at room temperature. After the incubation period, the 
diameter of the bacterial growth in both swimming and swarming plates was measured. Both 
assays were made in triplicate. 
3.3 Expression of compounds with antimicrobial activity 
Different conditions were tested in order to obtain the best production yield of 
compounds with antimicrobial activity. In this study, Stenotrophomonas maltophilia ΔphoQ and 
D457 strains were grown in, solid and liquid, LB and M9 minimal medium supplemented with 
casamino acids and glucose. 
3.3.1 Liquid medium 
Two 500 ml Erlenmeyer flasks with 200 ml of either LB medium or M9 minimal medium 
supplemented with glucose and casamino acids were inoculated with 25 µl of pure over-night 
(16 hours) cultures of the Stenotrophomonas maltophilia D457ΔphoQ mutant strain and 
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Stenotrophomonas maltophilia D457 parental strain, and incubated for 24, 48 and 72 hours in 
a MaxQ 4000 orbital shaker at 30 ºC 200 rpm. For each medium, the same volume of non-
inoculated medium were incubated in the same conditions and used as controls. 
3.3.2 Solid medium 
Batches composed of six plates of lysogeny agar medium (LA, 1.5 % commercial agar) 
each with 15 ml of medium were inoculated with 100µl of a pure over-night (16 hours) culture 
of each producing strains separately, with the optical density (OD) at 600 nm adjusted to 0.02 
units. Cells were seeded across the medium using sterile glass spheres by shaking vigorously 
for about 30 seconds, in order to grow in a uniform layer of cells. The plates were incubated 
for 24, 48 and 72 hours at 30 ºC. 
Equal amount of M9 minimal medium plates supplemented with casamino acids and 
glucose plates were inoculated in the exact same conditions. For each medium, the same 
amount of non-inoculated plates were incubated in the same conditions and used as controls. 
3.4 Active Compounds Isolation 
To test higher concentrations of the antimicrobial compound, to have a less chemically 
complex sample for further analysis and to determine the polarity of the active compound(s) 
sequential extractions involving three organic solvents, Dichloromethane (DCM), Ethyl Acetate 
(EA) and methanol (MeOH) were performed. The following extractions were only targeted for 
extracellular compounds, hence the cellular pellets were discarded. 
3.4.1 Liquid-Liquid Extraction 
Cultures growing in Erlenmeyer’s as mentioned in 3.3.1, were centrifuged in a  
Beckman J2-21 centrifuge, at 8500 rpm, and 4 ºC, for 15 minutes, and further filtered using 
sterile Minisart® 0.45 µm filters in order to completely remove any suspended cells. 
Subsequently, the recovered supernatant was poured into a chemically sterile pear-shaped 
separatory funnel, and the partitioning was carried out according to the  Kupchan method, with 
slight modifications (VanWagenen et al. 1993). The first organic solvent added was DCM in a 
1:1 proportion. The mixture was shaken vigorously for 5 minutes and left for settling until both 
phases were completely distinct and able to collect the organic solvent. This procedure was 
repeated 3 times. After the last DCM extraction, the same volume of EA was added and the 
extraction was carried out as described above. Finally, a spoonful of anhydrous sodium 
sulphate was added to each of the fractions to remove any water that might have been dragged 
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in the separation process. Then, both fractions were filtered (Machery-Nagel® MN 615 filter 
paper) to remove the sodium sulphate. 
3.4.2 Solid-Liquid Extraction 
Producing strains growing in solid medium as described in 3.3.2, were carefully 
removed from the agar and discarded. Then, the cleaned agar was cut in squares with 2 cm 
height and transferred to a 500 ml Erlenmeyer flask. DCM (200 ml) was added to the 
Erlenmeyer and the extraction was carried out by shaking the flask for one hour at 200 rpm, at 
room temperature. The liquid phase was then recovered and filtered (Machery-Nagel® MN 
615 filter paper) to remove any traces of agar from the DCM fraction and anhydrous sodium 
sulphate added. The extraction process was repeated twice. After the last extraction with DCM, 
the same volume of the second organic solvent (EA) was added to the Erlenmeyer flask 
containing the agar and the sequential extraction was concluded in the same conditions as 
referred above. Finally, the extraction was completed with MeOH in the same conditions, 
except for the addition of anhydrous sodium sulphate. 
3.4.3  Extract Concentration 
The resulting solutions from the sequential extractions were concentrated at 40 ºC, 
under low pressure (640 mbar for DCM fraction, 200 mbar for EA fraction and gradually 
lowering the pressure until reaching 40 mbar for MeOH and H2O fractions), in a BUCHI rotary 
evaporator. After complete dryness, the residue was suspended in 200 µl of DMSO for further 
biological assays, and/or suspended in 200 µl of the respective organic solvent, from witch 50 
µl were reserved for further analysis by thin layer chromatography (TLC) and gas 
chromatography-mass spectrometry (GC-MS).  
3.5 Biological Activity Assays 
3.5.1 Cross-Streak Assay 
A simple cross-streak assay was performed as 
described by Williston (Williston et al. 1947), with slight 
modifications. In this assay, a fresh culture of the producing 
strain was streaked horizontally in the centre of the LA 
medium plates for 3 days and incubated at 37 ºC. After 72 
hours, the test strains were streaked at right angles and 
further incubated for another 16 hours at 37 ºC. The inhibition 
Producing strain 
Test strains 
Test strains 
Fig. 2 - Schematic 
representation of the cross-
streak assay layout. 
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was evaluated by measuring the length of the inhibition zones (mm). 
3.5.2 Agar-Well Diffusion Method 
Crude samples of the filtered supernatant mentioned in 3.3.1 were tested for the 
presence of inhibitory compounds using a modified agar well-diffusion method described by 
Paik and Glatz (Paik & Glatz 1995). For this assay, the medium was poured into the petri 
dishes about 5 mm deep, in a horizontal laminar flow chamber. The plates were dried for 2 
hours in said laminar flow chamber, to facilitate sample diffusion. Then, each plate was divided 
in four equally sized quadrants and a 5mm well was cut in their centre. Afterwards, 50 µl of 
each sample was transferred into the well and the test strains streaked vertically and 
horizontally around the well. The plates were incubated at 37 ºC and after 16 hours observed 
for growth inhibition. Wells which were filled with non-inoculated medium served as controls. 
3.5.3 Drop Diffusion Method 
The samples resolved in DMSO mentioned in 3.4.3 
were tested for antimicrobial activity using the drop diffusion 
method mentioned by Hili and Evans (Hili et al. 1997), with 
slight modifications. After diluting overnight cultures of the 
test strains to and OD600 of 0.02, 100µl of culture was spread 
in LA plates using glass pearls so only a single layer of cells 
would grow in the medium. After allowing the cells settle and 
the plates dry for 10 minutes, a single 5 µl drop of each 
sample was carefully placed in the respective test area and 
the plates were incubated at 37ºC for 24 hours, after which 
the diameter of the inhibition the inhibition zones was measured. For each sample a minimum 
of 3 replicates was performed. 
  
Fig. 3 – Schematic 
representation of the Drop 
Diffusion Method layout. 
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3.6 Structure Elucidation 
3.6.1 Thin layer chromatography (TLC) 
Analytical TLC was carried out on silica gel UV254 plates with 0.2 mm thickness, 20 x 
20 cm, (Alugram® Xtra SIL G Aluminium, Macherey-Nigel). Before a single drop was placed 
on the TLC plates, they were cut into 12 x 7.5 cm parts, allowing 6.5 cm of effective migration 
distance. After allowing the drop to dry, plates were developed using a mixture of DCM and 
methanol (10:1) as mobile phase, and placed in a vertical glass chamber at room temperature. 
After migration, the plates were dried under pressurised air and the spots were observed under 
UV light at 254 and 366 nm. Then, the plates were pulverized with a solution of concentrated 
sulphuric acid (10%) in ethanol and, finally, burned with a Power Plus heat gun, in order to 
permanently reveal the spots. 
3.6.2 Gas chromatography-Mass spectrometry (GC-MS) 
Samples obtained in 2.3.3 were analysed by GC-MS, in order to tentatively identify the 
bioactive compound(s). The analysis was performed using a Thermo Scientific Trace GC Ultra 
gas chromatography equipment, coupled to a Thermo Scientific ITQ 900 ion trap mass 
spectrometer. The mass range for this run was 50 to 400 (m/z) in positive ion mode. GC 
analysis were performed on a  Bruker fused silica column (30.0 m x 0.25 mm I.D., 0.25 µm film 
thickness; 5% phenyl / 95% dimethylsiloxane) and helium was used as gas career. Mass 
analysis were performed by the standard impact electron ionization mode. The GC run was 
performed with and oven temperature of 200 ºC starting from 50 ºC (15 ºC/min increase), with 
a 1/10 split rate at 12 ml/min with an inlet temperature of 250 ºC. Chromatograms and mass 
spectra data were collected and analysed with the Thermo Scientific Xcalibur program. 
3.7 Protein Quantification 
For protein quantification purposes the strains were grown in a minimal medium to 
reduce the interferences caused by medium constituents, therefore ΔphoQ and D457 strains 
were grown in M9 agar plates as described in 3.3.2. After 72 hours of incubation, two solid-
liquid extractions were performed with methanol as described in 3.4.2. After the methanolic 
fractions were filtered, phenylmethanesulfonyl fluoride (PMSF) dissolved in isopropanol was 
added to each Erlenmeyer to an end concentration of 1mM to prevent protein degradation 
during the evaporation process of the MeOH (Thermo Scientific 2014). The fractions were 
evaporated as described in 3.4.3 with a starting pressure of 350 mbar and gradually reducing 
the pressure to 40 mbar, since the methanolic extraction dragged a considerable amount of 
water from the M9 agar plates. 
19 
 
3.7.1 Spectrum analysis and Protein Quantification by UV  
In order to obtain absorbance spectrums of the methanolic extracts obtained in 3.7, the 
samples were diluted (1:50) to produce on-scale readings, and 1 mL of each sample was 
transferred into an individual quartz cuvette. After zeroing the UNICAM UV2 
spectrophotometer with a water filled quartz cuvette, the wavelength range tested was 228 to 
700 nm with 2.0 nm bandwidth and at a variable speed controlled by the spectrophotometer’s 
Inteliscan feature. The absorbance spectrums were recorded and analysed with MS Excel 
2013.  
3.7.2 Biuret assay 
Protein quantification via the biuret method was performed in a 96 well polystyrene 
microplate. In this assay, 40 µl of water (used as control), 40 µl of standard solution of bovine 
serum albumin (BSA) in 7 different concentrations (0 to 5 mg/mL) and 40 µl of the two samples 
prepared in 3.7 were transferred in triple to the microplate wells (table in annex). After 
transferring all the solutions into its respective well, 200 µL of biuret reagent (300 mL of 10% 
(w/v) NaOH to 500 mL of a solution containing 0.3% copper sulphate pentahydrate and 1.2% 
sodium potassium tartrate, then diluted to 1 L of H2O MilliQ) was added to each well and the 
mixture homogenized with the micropipette. The microplate was then wrapped with tin foil to 
protect from light and incubated for 20 minutes at room temperature for colour development. 
The values of absorbance were measured with the microplate reader Zenyth 3100 at 540 nm 
with steering at room temperature and the obtained absorbance readings were plotted against 
the calibration curve in order to determine the protein concentrations. 
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4. Results and discussion 
4.1 Growth characteristics 
The motility assays described in 3.2, allowed the assessment of the phenotypic stability 
of the mutant. This was possible because previous work showed that the mutant ΔphoQ had 
increased motility over the parental D457, which was verified regularly during the 
assessments. 
Fig. 4 - Motility differences between the D457 and the ΔphoQ strain. Each experiment was 
performed in triple and the error bars represent the standard deviation for each data set. 
The mobility assessment allowed 
to verify the integrity of the mutant by 
comparing the growth pattern of the two 
strains. In this case the mutant showed, 
as expected, a significant increase of 
motility capabilities. The growth diameter 
of the mutant in the swimming assay was 
in average 13 times higher than the 
parental strain, 74 mm and 5.6 mm 
respectively. The mutant strain also 
showed a significant increase in 
swarming motility compared to the 
parental strain, the ΔphoQ mutant strain managed to travel 31.3 mm, while the D457 parental 
strain 9 mm. Additionally, this assay allowed us to observe the production of a putative enzyme 
with agarase characteristics. The production of this putative agarase was only present in the 
mutant strain ΔphoQ and this event was able to be reproduced several times, however what 
triggered such event is still not of our knowledge. In average, only 1 out of 3 plates would show 
Fig. 5 – Production of a putative agarase by the 
mutant S. maltophilia ΔphoQ grown in LA 0.3 % agar. 
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agar degradation, always starting from the periphery of the plate and slowly dissolving the agar 
leading to accumulation of gas in this area. Even though we never registered agar degradation 
by the parental strain D457, according to KEGG database this strain contains in its genome 
two genes which putatively encode for two agarases. One being the alpha-agarase and the 
other the beta-agarase, EC 3.2.1.158 and EC 3.2.1.81 respectively (Kanehisa & Goto 2000; 
Kanehisa et al. 2014). The first one was first isolated from a Thalassomonas sp., and is 
responsible for endohydrolysis of (1->3)-alpha-L-galactosidic linkages in agarose, yielding 
agarotetraose as the major product (Ohta et al. 2005). The second one, firstly isolated from a 
marine Vibrio, hydrolyse the (1->4)-beta-D-galactosidic linkages in agarose randomly. Both 
use agarose as main substrate but they can use other substrates like agarohexaose, 
neoagarohexaose and porphyran (Jam et al. 2005). The described mutation in the virulence 
related PhoQ operon, results, as shown, in a noticeable alteration in the bacteria’s phenotype. 
Additionally, to this cellular changes wouldn’t be surprising if changes at a metabolic level 
would arise as well from this mutation. The production of a putative agarase is evidence that 
the mutation triggered the activation of certain, previously inactivated, metabolic pathway(s). 
Because the phoP-phoQ operon is directly related with the regulation of virulence (Kasahara 
et al. 1992), would be plausible if the metabolism of a toxin would be affected by a mutation in 
one of the genes, either up-regulated of down-regulated. Taken this hypothesis into account, 
screenings for antimicrobial agents were conducted. 
4.2  Biologic Assays 
To properly assess the antimicrobial activity of the unknown compound produced by 
the ΔphoQ mutant, four different biologic assays were performed. Results obtained from the 
first three assays, namely the “dot assay”, cross-streak assay and agar-well diffusion assay, 
did not suggest the production of a compound with antimicrobial activity by any of the two 
strains (data not shown). In the cross-streak assay, antimicrobial activity is detected when one 
of the streaks of the test strain fail to grow near the previously streaked producing strain, which 
in this case did not occur, all the test strains managed to grow from the periphery of the LA 
plate to the area near the producing strain. The same was observed in the “dot-assay” and 
agar-well diffusion methods, in these two cases a halo of inhibition was expected to be 
observed if a high enough concentration of antibiotic was produced by the producing strain. 
Since no inhibition was observed with these approaches, no actual conclusion could be made 
about whether or not the strains produced a biological active molecule. 
There are several possible justifications for the absence of inhibition zones in this 
particular case, the first being that the organism do not produce a antimicrobial compound to 
the extracellular space, the second one is that the organism does not produce the compound 
at all or maybe he does produce a biologically active compound but only in small quantities, 
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leading to a very low extracellular concentration of compound which can lead to a 
misinterpretation of its actual presence/absence. 
Consequently, to increase the compound(s) concentration, the organic extracts 
resolved in DMSO were submitted to the biological susceptibility assay Drop Diffusion assay. 
Since molecules tend to dissolve according to the solvent’s polarity (polar molecules dissolve 
in polar solvents and non-polar molecules dissolve in non-polar solvents), this method also 
allowed to understand the polarity of the unknown compound(s), as each of the four solvents 
used in the extraction process, had its own level of polarity. Starting from the least polar solvent 
the sequence goes as follows: dichloromethane, ethyl acetate, methanol and water. The 
extracts obtained in 3.4.3 of the two different stains could be described as a light yellow 
powder, except for the extract relative to the mutant grown for 72 hours in LA, which had a 
dark yellow or orange colour. The extracts were dissolved in DMSO to a final concentration of 
10 mg/ml and were used in the biologic drop-diffusion assay. Results obtained from these 
assays showed that the ethyl acetate extract from the LA medium inoculated with ΔphoQ 
mutant had clear inhibition zones around the spot where the 5 µL of sample was applied. Most 
of the inhibition halos were the same size, around 10 to 11 mm. The biggest inhibitory halo 
was observed on the EA extract of ΔphoQ, grown for 72 hours in LA medium, against E. 
faecalis ATCC 29212 with 32 mm. Small inhibition zones were also occasionally visible in the 
ethyl acetate fractions of solid M9 minimal medium inoculated with ΔphoQ mutant. No inhibition 
zones against the test strains were observed for the remaining fractions (dichloromethane, 
methanol or water) of ΔphoQ mutant, and organic extracts of non-inoculated medium 
Fig. 6 –Photos of the Drop-Diffusion assay, taken to the two most inhibited strains E. faecalis 
ATCC29212 (A) and S. maltophilia D457 (B). The big halos of inhibition are relative to the AE fraction 
of 72 hours grown ΔphoQ in LBA. 
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(controls). Most interesting of all no fractions, organic or inorganic, of the D457 parental strain 
showed inhibitory activity. It has been shown that the growth patterns of the parental strain and 
the mutant are identical in LB and M9, hence this observed difference regarding the fractions 
biological activity might be due to an increase of active compound production per cell 
(Zwerschke 2012). Additionally, drop diffusion assays with extracts obtained from non-
sequential extractions with EA were performed, and the activity results were identical to the 
ones obtained by the sequential extraction method. A non-sequential extraction with EA, is an 
extraction performed solely with a single solvent, in this case, EA. Thus, would be expected 
that the sample was more enriched and subsequently more active. This was not verified, since 
the activity levels of the sample remained equal. This could mean that the compound(s) 
responsible to the antimicrobial activity, has low to none affinity to DCM, and in a sequential 
extraction it will always dissolve in the less non-polar solution. 
The table 4 below compiles the inhibition results obtained in the drop diffusion assay. 
The fractions which did not show any inhibitory effect are omitted. The average results were 
calculated with the results obtained in three independent assays. 
 
Table 3- ΔphoQ mutant strain’s spectrum of activity against test organisms. The different ranges 
of extent inhibition are represented by the following scale: - = no inhibition (0 to 5 mm); + = positive 
inhibition (6-11 mm); ++ = 12 to 17 mm; +++ = 18 to 23 mm. 
 
Test strain 
Producing 
strain 
Fraction 
Extent of 
inhibition 
Average 
inhibition 
diameter (mm) 
S. maltophilia D457R 
 ΔphoQ EA-LA-72h + 11.3 
B. cereus ATCC 11778 
 ΔphoQ EA-LA-72h + 11.2 
E. coli MultiR 
 ΔphoQ EA-LA-72h + 10.3 
S. aureus MRSA 
 ΔphoQ EA-LA-72h + 11.7 
E. coli ESBL 
 ΔphoQ EA-LA-72h + 10.2 
E. faecalis ATCC 29212 
 ΔphoQ EA-LA-72h +++ 21.3 
 ΔphoQ EA-M9A-72h + 11.3 
P. aeruginosa PAO1 
 ΔphoQ EA-LA-72h + 11.7 
A. haemolyticus VR 
 ΔphoQ EA-LA-72h + 10.3 
S. maltophilia D457 
 ΔphoQ EA-LA-72h ++ 15.3 
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These results strongly suggest that the compound is produced in the later phases of 
incubation in long stationary phase, since none of the batches grown for 24 and 48 hours 
inhibited the growth of any test strain. Moreover, because the compound production seems to 
be associated with the stationary phase, we could assume that it is a by-product of the 
secondary metabolism, as at this phase, the primary metabolism has greatly ramped down 
(Barrios-Gonzáles et al. 2003). This is the scenario in which several antibiotic molecules are 
produced. For example, penicillin biosynthesis by Penicillium chrysogenum starts when 
glucose is exhausted from the culture medium and the fungus starts consuming lactose. Most 
secondary metabolites of economic importance are produced by actinomycetes, particularly of 
the genus Streptomyces, and by fungi (Barrios-Gonzáles et al. 2003). Unlike primary 
metabolites, such as amino acids or nucleotides that are essential for the microbe’s growth 
and survival, secondary metabolites are not. It is now generally accepted that antibiotics do 
have a role in a sort of inter-microbial warfare that is waged amongst the inhabitants of the 
same ecological niche in competition for the limited nutrients available for growth and survival 
(Dougherty & Pucci 2012). With lower production yields than the primary metabolism, 
secondary metabolites are produced at very low concentrations, compared with the primary 
metabolites, moreover the conditions at which they are produced have to be perfectly 
controlled to obtain reproducible results. These lower production yields result from the 
activation of a complex cascade of regulatory events triggered by either the depletion of a key 
nutrient or by the presence of an inducer. At this point, as most the primary metabolism stalls, 
some branches of the primary metabolism remain active as pathways for secondary 
metabolism (Demain 1998). The reason why this kind of cellular activity is more predominant 
in the stationary phase is precisely because the cells are suffering from starvation stress, 
among others like, pH and oxidative (Barrios-Gonzáles et al. 2003). 
Secondary metabolite diversity is very wide. Antibiotics, pigments, toxins, effectors of 
ecological competition and symbiosis, pheromones, enzyme inhibitors, immunomodulation 
agents, receptor antagonists and agonists, pesticides, antitumor agents and growth promoters 
of animals and plants are all examples of secondary metabolites classes (Demain 1998). 
Associated with such great diversity in compound classes and functions are, of course, even 
greater structural diversity of these of these compounds. In order to identify de class and/or 
structure of our biologically active compound, protein quantification and GC-MS assays were 
conducted. 
 
 
 
25 
 
4.3 Protein quantification 
Protein concentrations of the fractions obtained in 3.7 were evaluated by two separate 
means. Firstly, the absorbance spectrums resulting from the parental and the mutant strains 
had a lot of noise and interferences. This was expected since we were working with a highly 
complex solution, and it is known that different proteins and nucleic acids present in the 
methanolic extract will interfere with the reading generating a considerable error, as well as 
the presence of other non-protein compound in the mixture which absorbs ultraviolet light 
(Olson & Markwell 2007). However, the readings obtained revealed a remarkable 
heterogeneity between the extracellular contents of both strains. Additionally, at 280 nm 
wavelength, which is where most proteins absorb light because of tyrosine and tryptophan side 
chains, the ΔphoQ mutant showed a level of absorbance almost three times greater than the 
D457 parental strain. The absorbance were 0.817 and 0.279, respectively. Since the protein 
mixture analysed was unknown, the molecular weight is also unknown, which makes 
impossible to determine the molar absorption coefficient and ultimately the exact final 
concentration. Nonetheless, a rough estimative of protein concentration can be calculated in 
these circumstances using the following formula Concentration (mg/ml) = (1.55 x A280) - 0.76 
x A260) (Layne 1957). According to this formula, the mutant produces 10 times more 
extracellular proteins than its parental strain, with an estimate value of 1.266 mg/ml and 0.0124 
mg/ml of proteins, respectively. 
To further investigate the protein concentration in these two solutions the biuret protein 
assay was performed. This method relies on the ability of peptides containing three or more 
amino acid residues to form a coloured chelate complex with cupric ions in an alkaline 
environment containing sodium potassium tartrate. Biuret, a product of excess urea and heat, 
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Fig. 7 - Spectrum of absorbance of the methanol extract samples prepared in 3.7.1. The black 
vertical line marks the 280 nm wavelength at which most proteins are absorbed. 
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reacts with copper to form a light blue tetradentate complex. Single amino acids and dipeptides 
do not give the biuret reaction, but tripeptides and larger polypeptides or proteins will react to 
produce the light blue to violet complex that absorbs light at 540nm. Results obtained with the 
biuret assay, also suggested the presence of a higher protein concentration in the sample 
corresponding to the ΔphoQ mutant. The figure 8 represents the calibration curve for the biuret 
assay, in which is also represented the absorbance of our test samples. The sample with 
higher concentration was the methanolic extract from the ΔphoQ mutant with 3.99 mg/mL and 
the parental D457 strain exhibited a concentration of 1.72 mg/mL. The difference in protein 
concentration obtained via this assay is not of the same magnitude as the results obtained by 
UV analysis, nonetheless there is still a substantial difference in the order of more than two 
times higher between the ΔphoQ mutant and the D457 parental. This comparison was also 
possible since the same amount of cells were inoculated in the plates and both strains share 
identical growth patterns (Zwerschke 2012). These results obtained by two different 
techniques, suggest that the mutation in the phoQ gene somehow induced the production of a 
compound, or several, with protein-like characteristics. This increase in protein concentration 
may be linked to the increased production of the two previously mentioned enzymes alpha- 
and beta-agarases by the ΔphoQ mutant, however that relation has yet to be further studied. 
Another possible source of this increased concentration of peptides can be related with the 
overproduction of nonribosomal peptides (NRPs). The bacteria S. maltophilia D457 is known 
to produce various nonribosomal peptides, and some of them with biological activity like 
vibriobactin, enterochelin and bacillibactin (Kanehisa & Goto 2000; Kanehisa et al. 2014). 
These molecules are siderophores as they kill bacteria by inducing iron starvation in the media 
by sequestering Fe2+ ions. Additionally, the metabolic pathway of these three siderophores is 
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directly linked to the 2,3- dihydroxybenzoic acid, a compound with known biological activity 
(George et al. 2011; Nguyen et al. 2013; Olano et al. 2009; Clardy et al. 2006), which 
accumulation can also be associated with the reported antimicrobial activity of the ethyl acetate 
extracts as the GC-MS results would further suggest. 
4.4 Thin layer chromatography assay 
A preliminary screening of the composition of the DCM, EA, and H2O extracts obtained 
from the ΔphoQ mutant and parental D457 strains was performed by thin layer 
chromatography (TLC). By observing the plate under UV light, it became evident that the 
mutation in the phoQ gene of S. maltophilia caused a profile shift in metabolites produced. As 
it is shown in the figure 9, the ΔphoQ mutant strain, exhibits 3 additional spots (only visible 
under UV light) compared to the chemical profile of the parental strain. This variation in 
chemical profiles was more accentuated in the 72 hour EA extract of cultures grown in solid 
M9 minimal medium. These results add strength to the hypothesis that the mutation in the 
phoQ gene, in fact, induce the production of compounds not produced by the parental strain. 
Additionally, taking in account the composition of the elution solution, we can affirm that 
the 3 extra spots visible in the mutant’s profile, are less non-polar that the remaining two, since, 
when using such mixture of solvents in the elution, the more non-polar a compound is, the it 
will migrate in the plate. 
Fig. 9 – TLC plates eluted with hexane/ethyl acetate (4/1). Bacteria grown in 
solid M9 minimal medium for 72 hours 37 ºC. Sample 1 (D457): low intensity spot 55 
mm above application level and high intensity spot at 49 mm and at the base; sample 
2 (ΔphoQ): 5 high intensity spots 55 mm, 49mm, 41mm, 26mm and 15mm; Sample 3 
(non-inoculated M9 + 1.5% agar): one visible spot at the base. 
1             2           3 
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4.5 Gas chromatography-Mass spectrometry analysis 
The samples obtained from the extraction with EA of the different mediums used for 
mutant strain’s growth were analysed by GC-MS in order to identify their chemical constituents. 
A comparison between the samples with and without biological activity in the drop-diffusion 
assay, allowed us to exclude the peaks that could be related with the antimicrobial activity. 
According to this strategy the peaks which are related to the antimicrobial activity in the EA-
LA-72h fraction are signalled in Fig. 10, corresponding to RT 18.20; 18.63; 22.45 and 27.71 
min.  
The MS spectra of each peak are depicted in Fig.12. Peaks 1 (RT 18.21 min), the major 
one, 2 (RT 18.63 min), and 4 (RT 27.71 min), show a prominent base peak at m/z 154 and a 
second abundant ion at m/z 70. These two characteristic fragment ions are also observed in 
peak 3 (RT 22.45 min) although the fragments at m/z 167 and m/z 139 are also remarkable. 
These common fragmentation patterns of compounds with distinct retention times suggest that 
such compounds may be isomers (Liu et al, 2009).The compounds were tentatively identified 
using the database of natural products NIST (National Institute of Standards and Technology, 
www.nist.gov) and in WILEY REGISTRY® of mass spectral data database. Although it was not 
found a full match compound, the 3,5-dihydroxybenzoic acid and the α-
phenylbenzenethanethioic acid, were proposed, suggesting a tendency to the benzoic acid 
family. In addition to the demonstrated antimicrobial activity of the Benzoic Acids against most 
of the strains used in this work, namely E. coli, S. aureus, P. aeruginosa, Bacillus spp. (Nguyen 
et al. 2013; George et al. 2011; Olano et al. 2009; Drăcea et al. 2007), they have the 
particularity to often form isomers with very distinct retention times (Liu et al. 2009). The 
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Fig. 10 - GC-MS chromatogram of the EA extract obtained from the growth of ΔphoQ mutant 
in LBA. 
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biologically active 2,3-dihydroxibenzoic acid compound, is also associated with the metabolic 
pathway of siderophores. These molecules are non-ribosomal peptides which also possess 
biological activity and its pathway is associated with the S. maltophilia’s metabolism (in silico 
data) (Kanehisa & Goto 2000; Kanehisa et al. 2014). 
Even though this information isn’t strong enough to support that our unknown 
compound is in fact a member of the benzoic acid compound family, it is plausible to suggest 
that the bioactive compound(s) might have cyclic rings in their structure, since several hits from 
the database search identified compounds with this characteristic, such as: isoguvacine, L-
histidine, 2-vinylnaphthalene, and of course di-hydroxybenzoic acid isomers. The compounds 
suggested by the GC-MS analysis software are depicted in fig. 11. All five compounds obey 
to all five rules of the “Lipinski’s rule of Five”, additionally, only the L-histidine (D) fails to meet 
the “rule of three”. This could mean that if our unknown compounds with biological activity are 
in fact similar to the ones suggested by the GC-MS analysis, there is a strong chance that they 
will be easily orally absorbed, and they have lead-like characteristics (Lipinski 2004; Lipinski 
et al. 2001; Congreve et al. 2003; Chemistry 2014). However, further studies have yet to be 
conducted to better understand the chemical structure of the unknown compounds, starting 
with the purification of the compounds to allow the performance of a nuclear magnetic 
resonance analysis, which would reveal the compound’s molecular structure.  
(B) 
(E) 
(C) 
(D) 
(A) 
Fig. 11 – Molecular structure of: (A) Benzoic Acid; (B) 2,3-
dihydroxybenzoic acid; (C) Isoguvacine; (D) L-histidine; (E); 2-
vinylnaphtalene. 
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5. Conclusion 
In this work, potentially-novel compounds were extracted from a S. maltophilia D457 
mutant. It was demonstrated that, when cultured in LBA at 37 ºC for 72 hours, the bacteria 
produces one or more compounds with antibacterial characteristics that can be extracted with 
ethyl acetate. The compound(s) activity was evident against several multidrug resistant 
bacteria, both gram positive and negative. It was of our best interest to identify such bioactive 
molecule(s) and so, a first approach to its structure elucidation was performed by GC-MS 
analysis. Even though it wasn’t possible to accurately identify the compound, hints about its 
possible molecular structure were revealed such as the presence of cyclic structures like 
benzene rings. 
Additionally, the ΔphoQ mutant exhibited production of a putative agarase when grown in 
solid medium with lower concentrations of agar, suited to promote bacterial motility. However, 
there was no evidence about the production of such compound by its parental strain S. 
maltophilia D457. Protein quantification assays suggested that this compound was associated 
with an increase of almost 3 times fold in protein production by the mutant strain compared to 
the parental strain. 
The next direction would be to further optimize the compound production by changing other 
culture conditions like osmotic pressure, pH and temperature followed by an assessment of 
which set of conditions trigger higher yields of compound production. Regarding compound 
identification, a scale up of the production process would be important to increase the amount 
of compound produced. Virtually, this would allow to obtain more overall product and therefore 
higher quantities of our unknown compounds. EA extracts will be submitted to a bio-guided 
fractionation by preparative column chromatography, followed by a final purification by semi-
preparative HPLC. The chemical structure of the isolated pure compounds will be 
accomplished by gas GC-MS and/or LC-ESIMS/MS followed by mono and dimensional NMR 
experiments. Taken together, these techniques can be regarded as a strong tool for molecular 
structure elucidation. Once we’ve obtained a purified compound, a biological activity 
comparison with standard antibiotics like penicillin, amoxicillin, tetracycline, in order to assess 
its efficiency compared with the antibiotics used nowadays in medical care. 
All this information compiled, might reveal itself widely important in the production of 
synthetic antibiotics, as the knowledge of the molecular structure of a compound with biological 
activity against a broad range of multidrug resistant bacteria, would evoke a great interest in 
attempting to replicate the characteristics which makes this/these compound(s) highly active. 
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7. Appendix 
Table 4 - Standard curve dilutions for the Biuret assay. 
Final [BSA] 
(mg/mL) 
Total BSA 
(µg) 
Vol. BSA 
Stock (µL) 
Water 
(µL) 
Biuret 
(µL) 
0.00 0 0.0 40 
200µL 
0.10 10 2.0 38 
0.25 20 4.0 36 
0.50 30 6.0 34 
1.00 40 8.0 32 
2.50 100 20.0 20 
5.00 200 40.0 0 
 
